Lifeworks Advisors LLC Trims Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Lifeworks Advisors LLC trimmed its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.8% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 5,126 shares of the biopharmaceutical company’s stock after selling 203 shares during the period. Regeneron Pharmaceuticals accounts for 1.1% of Lifeworks Advisors LLC’s portfolio, making the stock its 27th largest holding. Lifeworks Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $5,389,000 as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of the stock. Rakuten Securities Inc. raised its stake in shares of Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 19 shares during the period. Stephens Consulting LLC purchased a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $26,000. Sachetta LLC grew its stake in shares of Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 10 shares during the last quarter. Crewe Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the first quarter worth approximately $28,000. Finally, Lynx Investment Advisory bought a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter worth approximately $33,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock traded down $7.95 during midday trading on Thursday, reaching $796.38. 112,252 shares of the company traded hands, compared to its average volume of 522,228. The firm’s 50 day simple moving average is $1,000.06 and its two-hundred day simple moving average is $1,035.67. The firm has a market cap of $87.51 billion, a PE ratio of 19.90, a price-to-earnings-growth ratio of 3.10 and a beta of 0.15. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. Regeneron Pharmaceuticals, Inc. has a 1-year low of $784.96 and a 1-year high of $1,211.20.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the sale, the chief financial officer now owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 7.48% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on REGN. Citigroup initiated coverage on Regeneron Pharmaceuticals in a research note on Thursday. They issued a “neutral” rating and a $895.00 target price on the stock. TD Cowen raised their price target on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the stock a “buy” rating in a research note on Tuesday, July 23rd. Wells Fargo & Company lowered their price objective on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating for the company in a research report on Tuesday, October 22nd. Evercore ISI dropped their target price on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. Finally, BMO Capital Markets decreased their price target on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a research note on Friday, November 1st. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and eighteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $1,097.14.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.